Creative Medical Technology (NASDAQ:CELZ) Share Price Passes Below Fifty Day Moving Average – Here’s What Happened

Creative Medical Technology Holdings, Inc. (NASDAQ:CELZ) shares crossed below its 50-day moving average during trading on Monday . The stock has a 50-day moving average of $1.50 and traded as low as $0.62. Creative Medical Technology shares last traded at $0.65, with a volume of 249,764 shares traded.

Wall Street Analyst Weigh In

Separately, Weiss Ratings lowered Creative Medical Technology from a “sell (d-)” rating to a “sell (e+)” rating in a research note on Friday. One equities research analyst has rated the stock with a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat.com, the stock has a consensus rating of “Reduce”.

Creative Medical Technology Price Performance

The stock has a market capitalization of $3.08 million, a P/E ratio of -0.30 and a beta of 1.95. The company’s 50 day simple moving average is $1.50 and its two-hundred day simple moving average is $1.86.

Creative Medical Technology (NASDAQ:CELZ) last posted its earnings results on Friday, May 8th. The company reported ($0.38) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.39) by $0.01. On average, research analysts anticipate that Creative Medical Technology Holdings, Inc. will post -1.14 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Creative Medical Technology

A hedge fund recently bought a new stake in Creative Medical Technology stock. Jane Street Group LLC bought a new position in shares of Creative Medical Technology Holdings, Inc. (NASDAQ:CELZ) during the 4th quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor bought 30,205 shares of the company’s stock, valued at approximately $59,000. Jane Street Group LLC owned about 1.17% of Creative Medical Technology as of its most recent filing with the Securities & Exchange Commission. Hedge funds and other institutional investors own 1.42% of the company’s stock.

About Creative Medical Technology

Creative Medical Technology Holdings, Inc (NASDAQ: CELZ) is a clinical‐stage biotechnology company focused on the development, manufacture and commercialization of exosome‐based therapies derived from human bone marrow mesenchymal stem cells. The company’s proprietary exosome platform is being investigated for applications in regenerative medicine, aesthetic dermatology, wound healing and anti‐inflammatory treatments. Creative Medical leverages cGMP manufacturing processes to produce sterile, cell‐free exosome formulations designed to support tissue repair and cellular rejuvenation.

The company’s lead product candidates include XoFlo, an exosome enrichment product intended for use in musculoskeletal and soft tissue injuries, and specialized formulations targeting skin rejuvenation and scar reduction.